Arcellx, Inc. Share Price

Equities

ACLX

US03940C1009

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 24/05/2024 BST 5-day change 1st Jan Change
51.9 USD +2.51% Intraday chart for Arcellx, Inc. -3.21% -6.49%
Sales 2024 * 95.61M 7.51B Sales 2025 * 98.59M 7.74B Capitalization 2.78B 218B
Net income 2024 * -97M -7.62B Net income 2025 * -126M -9.89B EV / Sales 2024 * 22.5 x
Net cash position 2024 * 629M 49.42B Net cash position 2025 * 531M 41.7B EV / Sales 2025 * 22.8 x
P/E ratio 2024 *
-27.5 x
P/E ratio 2025 *
-24.9 x
Employees 130
Yield 2024 *
-
Yield 2025 *
-
Free-Float 79.83%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.51%
1 week-3.21%
Current month+3.76%
1 month+1.01%
3 months-16.30%
6 months-2.59%
Current year-6.49%
More quotes
1 week
50.44
Extreme 50.44
55.45
1 month
47.88
Extreme 47.88
55.85
Current year
47.88
Extreme 47.88
75.10
1 year
30.74
Extreme 30.74
75.10
3 years
6.04
Extreme 6.035
75.10
5 years
6.04
Extreme 6.035
75.10
10 years
6.04
Extreme 6.035
75.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 21/01/21
Director of Finance/CFO 32 22/05/22
Chief Tech/Sci/R&D Officer 53 31/03/20
Members of the board TitleAgeSince
Director/Board Member 60 31/07/20
Director/Board Member 48 31/01/15
Chief Executive Officer 45 21/01/21
More insiders
Date Price Change Volume
24/05/24 51.9 +2.51% 438,255
23/05/24 50.63 -6.69% 849,673
22/05/24 54.26 +1.86% 404,970
21/05/24 53.27 -2.01% 582,233
20/05/24 54.36 +1.38% 305,355

Delayed Quote Nasdaq, May 24, 2024 at 09:00 pm

More quotes
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
51.9 USD
Average target price
80.57 USD
Spread / Average Target
+55.24%
Consensus